Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,172
  • Shares Outstanding, K 29,439
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,940 K
  • 60-Month Beta 2.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.80
Trade ZYNE with:

Options Overview

Details
  • Implied Volatility 166.55%
  • Historical Volatility 208.49%
  • IV Percentile 55%
  • IV Rank 13.46%
  • IV High 596.36% on 03/09/20
  • IV Low 99.69% on 07/22/20
  • Put/Call Vol Ratio 0.14
  • Today's Volume 256
  • Volume Avg (30-Day) 5,756
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 19,497
  • Open Int (30-Day) 34,364

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.38
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.47
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +16.62%
on 03/05/21
9.00 -54.00%
on 02/10/21
-1.60 (-27.87%)
since 02/08/21
3-Month
3.15 +31.43%
on 12/29/20
9.00 -54.00%
on 02/10/21
-0.28 (-6.33%)
since 12/08/20
52-Week
2.55 +62.35%
on 03/17/20
9.00 -54.00%
on 02/10/21
+0.12 (+2.99%)
since 03/06/20

Most Recent Stories

More News
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.

ZYNE : 4.14 (-0.24%)
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 4.14 (-0.24%)
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.

ZYNE : 4.14 (-0.24%)
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.

ZYNE : 4.14 (-0.24%)
/R E P E A T -- Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug/

/R E P E A T -- Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug/

ZYNE : 4.14 (-0.24%)
NOVA.CN : 0.155 (unch)
NMLSF : 0.1262 (-1.33%)
Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

ZYNE : 4.14 (-0.24%)
NOVA.CN : 0.155 (unch)
NMLSF : 0.1262 (-1.33%)
Thinking about buying stock in Zomedica, Zynerba Pharmaceuticals, Cronos Group, Hexo Corp, or AzurRx BioPharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, ZYNE, CRON, HEXO, and AZRX.

ZOM : 1.8800 (+5.62%)
CRON : 9.44 (-0.42%)
ZYNE : 4.14 (-0.24%)
AZRX : 1.2100 (unch)
HEXO : 6.49 (+1.09%)
Thinking about buying stock in Zomedica, Sundial Growers, Senseonics Holdings, Phunware, or Zynerba Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, SNDL, SENS, PHUN, and ZYNE.

SENS : 2.52 (+1.61%)
ZOM : 1.8800 (+5.62%)
PHUN : 1.5600 (+19.08%)
SNDL : 1.1800 (+3.96%)
ZYNE : 4.14 (-0.24%)
Thinking about buying stock in Zomedica, Nokia, Zynerba Pharmaceuticals, Senseonics Holdings, or Atossa Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NOK, ZYNE, SENS, and ATOS.

SENS : 2.52 (+1.61%)
ZOM : 1.8800 (+5.62%)
ZYNE : 4.14 (-0.24%)
ATOS : 2.13 (-4.48%)
NOK : 3.87 (-0.26%)
Thinking about buying stock in Sundial Growers, Sellas Life Sciences, Selecta Biosciences, Outlook Therapeutics, or Zynerba Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, SLS, SELB, OTLK, and ZYNE.

OTLK : 1.8100 (-0.55%)
SELB : 3.70 (-2.37%)
SLS : 9.08 (+15.08%)
SNDL : 1.1800 (+3.96%)
ZYNE : 4.14 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

3rd Resistance Point 4.55
2nd Resistance Point 4.43
1st Resistance Point 4.28
Last Price 4.14
1st Support Level 4.01
2nd Support Level 3.89
3rd Support Level 3.74

See More

52-Week High 9.00
Fibonacci 61.8% 6.54
Fibonacci 50% 5.78
Fibonacci 38.2% 5.01
Last Price 4.14
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar